Donafenib Clinical Trials
7 recruitingDrug
Phase 23Not Applicable2
Showing 1–7 of 7 trials
Recruiting
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma Non-resectable
Ze-yang Ding, MD300 enrolled2 locationsNCT05713994
Recruiting
Phase 2
Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk
Biliary Malignant Tumors
The First Affiliated Hospital with Nanjing Medical University70 enrolled1 locationNCT06685289
Recruiting
Phase 2
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
Locally Advanced Thyroid Gland Carcinoma
West China Hospital75 enrolled1 locationNCT06482086
Recruiting
Not Applicable
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
Hepatocellular CarcinomaRecurrent TumorMicrowave Ablation+1 more
Sun Yat-sen University108 enrolled1 locationNCT06609876
Recruiting
Phase 2
TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension
Hepatocellular Carcinoma with PVTT
Fei Gao40 enrolled1 locationNCT06646198
Recruiting
Not Applicable
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
Hepatocellular CarcinomaAdjuvant Therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University204 enrolled1 locationNCT06581315
Recruiting
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma Non-resectable
Tongji Hospital300 enrolled4 locationsNCT05717738